Saurabh Mehandru, MD
Gastroenterology · New York, NYNPI 1972536035
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $52,491 of the $54,903 with a category attached, or 95.6%. 9 manufacturers reported payments, led by GSK at 44.4% of the total. Reporting peaked in 2019 at $24,378 and has fallen 86.4% since, to $3,322 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 39 payments — averaging $1407.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- E.r. Squibb & Sons, L.L.C.$7K
- Genentech, Inc.$6K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
- Ferring Pharmaceuticals AS$5K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- plus $3K from 3 others
Across 5 payments — averaging $80,969 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$404K
- Takeda Pharmaceuticals U.S.A., Inc.$900
What the payments were for
- Consulting fees$52,49196%
- Travel & lodging$1,3923%
- Food & beverage$1,0002%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $24,378 |
| E.r. Squibb & Sons, L.L.C. | 10 | $6,724 |
| Genentech, Inc. | 2 | $6,440 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $5,790 |
| Ferring Pharmaceuticals AS | 3 | $4,750 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $3,480 |
| Merck | 1 | $3,200 |
| Amgen | 1 | $122 |
| Sandoz | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,903 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 12 | $5,453 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 40 | $662 |
| Omeprazole | 25 | $260 |
| Pantoprazole Sodium | 12 | $175 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.